Autologous adoptive T-cell therapy in which patient-derived tumor-reactive T cells are expanded ex vivo and reinfused to recognize peptide-HLA complexes via native T-cell receptors, activating cytotoxic effector functions (perforin/granzyme and cytokines) to kill tumor cells.
Autologous tumor-infiltrating T cells are expanded ex vivo and reinfused to recognize tumor peptide–HLA complexes via their native T‑cell receptors, triggering TCR signaling and cytotoxic effector functions (perforin/granzyme release and cytokine secretion) to kill tumor cells.
Adoptively transferred tumor‑reactive T cells recognize the tumor peptide–HLA‑B complex via their native TCR and directly kill the presenting cells through perforin/granzyme-mediated cytolysis and Fas–FasL–induced apoptosis.
Autologous adoptive T-cell therapy in which patient-derived tumor-reactive T cells are expanded ex vivo and reinfused to recognize peptide-HLA complexes via native T-cell receptors, activating cytotoxic effector functions (perforin/granzyme and cytokines) to kill tumor cells.
Autologous tumor-infiltrating T cells are expanded ex vivo and reinfused to recognize tumor peptide–HLA complexes via their native T‑cell receptors, triggering TCR signaling and cytotoxic effector functions (perforin/granzyme release and cytokine secretion) to kill tumor cells.
Tumor-reactive TCR T cells recognize the tumor peptide–HLA-C complex via their TCR and directly induce target-cell death via perforin/granzyme-mediated apoptosis (and Fas–FasL signaling).
Autologous adoptive T-cell therapy in which patient-derived tumor-reactive T cells are expanded ex vivo and reinfused to recognize peptide-HLA complexes via native T-cell receptors, activating cytotoxic effector functions (perforin/granzyme and cytokines) to kill tumor cells.
Autologous tumor-infiltrating T cells are expanded ex vivo and reinfused to recognize tumor peptide–HLA complexes via their native T‑cell receptors, triggering TCR signaling and cytotoxic effector functions (perforin/granzyme release and cytokine secretion) to kill tumor cells.
Tumor-reactive T cells recognize the tumor peptide–HLA-DR complex via their native TCR, triggering cytotoxic granule release (perforin/granzyme) and Fas–FasL signaling to induce apoptosis of target cells.
Autologous adoptive T-cell therapy in which patient-derived tumor-reactive T cells are expanded ex vivo and reinfused to recognize peptide-HLA complexes via native T-cell receptors, activating cytotoxic effector functions (perforin/granzyme and cytokines) to kill tumor cells.
Autologous tumor-infiltrating T cells are expanded ex vivo and reinfused to recognize tumor peptide–HLA complexes via their native T‑cell receptors, triggering TCR signaling and cytotoxic effector functions (perforin/granzyme release and cytokine secretion) to kill tumor cells.
Infused tumor-reactive T cells recognize the tumor peptide–HLA-DQ complex via their native TCRs and directly kill target cells through perforin/granzyme release and Fas–FasL–mediated apoptosis.
Autologous adoptive T-cell therapy in which patient-derived tumor-reactive T cells are expanded ex vivo and reinfused to recognize peptide-HLA complexes via native T-cell receptors, activating cytotoxic effector functions (perforin/granzyme and cytokines) to kill tumor cells.
Autologous tumor-infiltrating T cells are expanded ex vivo and reinfused to recognize tumor peptide–HLA complexes via their native T‑cell receptors, triggering TCR signaling and cytotoxic effector functions (perforin/granzyme release and cytokine secretion) to kill tumor cells.
Infused tumor-reactive T cells recognize the tumor peptide–HLA-DP class II complex via their native TCR and directly kill target cells by cytolytic synapse formation with perforin/granzyme release (and Fas–FasL apoptosis).